A Roadmap to Safe and Effective Bispecific Antibody Use in Myeloma: Mitigating and Managing Adverse Events
MAR 07, 2024
Description Community
About
CME credits: 0.25

Valid until: 07-03-2025

Claim your CME credit at https://reachmd.com/programs/cme/a-roadmap-to-safe-and-effective-bispecific-antibody-use-in-myeloma-mitigating-and-managing-adverse-events/17875/




Dive into the cutting-edge realm of bispecific antibodies for relapsed/refractory multiple myeloma with our experts, Dr. Caitlin Costello and Dr. Sagar Lonial. They explore the efficacy, safety, and practical integration of bispecific antibodies into clinical practice. Tune in to gain invaluable insights on optimizing patient care and navigating treatment-related adverse events to elevate your oncology practice.

=
Comments